Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Pfizer Inc. and Salix Pharmaceuticals.

2nd Annual Live Medical Crossfire®: Expert Exchanges in IBS and IBD

Release Date: July 15, 2021
Expiration Date: July 15, 2022

Activity Overview

This online, on-demand virtual symposium brings together faculty who are renowned clinician-researchers in the management of either irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) for an in-depth exploration of key aspects of care. In individual presentations, faculty review recent and emerging trial data and provide commentary on their clinical impact. Using panel discussions, patient cases are presented with clinical trial data tightly integrated to illuminate front-line, later-line, and maintenance therapy strategies. Adverse event recognition and management is educationally tied to case presentations. Future directions in the field will also be addressed and considered regarding how recent developments and highly anticipated trials may shape care. This educational activity is an archive of a live virtual symposium held on June 5, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Pfizer Inc. and Salix Pharmaceuticals.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is primarily directed toward gastroenterologists and primary care physicians. Nurse practitioners, physician assistants, pharmacists, researchers, and other health care professionals involved in the treatment and management of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Formulate an evidence-based plan for diagnosis of patients with suspected IBS and IBD
  • Evaluate efficacy and safety data for new and emerging treatments for IBS and IBD
  • Review current treatment guidelines for providing optimal care to patients with IBS and IBD
  • Develop management strategies for short-term and long-term management of IBD and IBS
  • Employ communication strategies and tools to build and improve the patient-clinician relationship

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Faculty

William D. Chey, MD
William D. Chey, MD
Professor of Internal Medicine
Professor of Gastroenterology & Nutritional Sciences
Director, GI Physiology Laboratory
Director, Digestive Disorders Nutrition & Lifestyle Program
University of Michigan
Ann Arbor, MI

Disclosures: Grant Research Support: Biomerica, Commonwealth Diagnostics International, QOL Medical, Urovant Sciences, Vibrant Pharma; Consultant: Biomerica, Ironwood Pharmaceuticals, QOL Medical, Ritter Pharmaceuticals, Salix Pharmaceuticals/Valeant, Takeda Pharmaceutical Co, Urovant Sciences, Vibrant Pharma.

Bruce E. Sands, MD, MS
Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant Research Support: Theravance Biopharma; Consultant: AbbVie, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare, Eli Lilly and Co, Genentech, Hoffmann-La Roche, Immunic, Ironwood Pharmaceuticals, Janssen, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka Pharmaceutical, Pfizer, Prometheus Laboratories, RedHill Biopharma, Shire, Takeda Pharmaceutical Co, Target PharmaSolutions, Theravance Biopharma.

Anita Afzali, MD, MPH, FACG, AGAF
Anita Afzali, MD, MPH, FACG, AGAF
Associate Professor of Medicine
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Medical Director, OSU Inflammatory Bowel Disease Center
Program Director, OSU Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
Columbus, OH

Disclosures: Grant Research Support: AbbVie, Bristol Myers Squibb, Janssen Pharmaceuticals, Takeda Pharmaceutical Co; Consultant: AbbVie, Celgene, Janssen Pharmaceuticals, Pfizer, Takeda Pharmaceutical Co; Speakers Bureau: AbbVie, Celgene, Janssen Pharmaceuticals, Pfizer, Takeda Pharmaceutical Co; Other: IBD Horizons.

Brooks D. Cash, MD, AGAF, FACG, FASGE
Brooks D. Cash, MD, AGAF, FACG, FASGE
Chief, Gastroenterology, Hepatology, and Nutrition
Dan and Lillie Sterling Professor of Medicine
UT Health Science Center at Houston
Endowed Director, Chao-Ertan Directorship
Memorial Hermann Hospital, Texas Medical Center
Houston, TX

Disclosures: Grant Research Support: Napo Pharmaceuticals; Consultant: AbbVie, Salix Pharmaceuticals, Takeda Pharmaceutical Co; Speakers Bureau: AbbVie, QOL Medical, Salix Pharmaceuticals, Takeda Pharmaceutical Co.

Lin Chang, MD
Lin Chang, MD
Vice-Chief, Vatche and Tamar Manoukian Division of Digestive Diseases
Program Director, UCLA GI Fellowship Program
Co-Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosures: Grant Research Support: AnX Robotica, Arena Pharmaceuticals, Vanda Pharmaceuticals; Consultant: Allergan, Arena Pharmaceuticals, Cosmo Pharmaceuticals, Ironwood Pharmaceuticals, Shire-Takeda; Shareholder: ModifyHealth; Other: Rome Foundation (royalties).

Adam Cheifetz, MD
Adam Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Medical Director, Infusion Services
Beth Israel Deaconess Medical Center
Professor of Medicine,
Harvard Medical School
Cambridge, MA

Disclosures: Grant Research Support: Inform Diagnostics; Consultant: AbbVie, Arena, Bacainn Therapeutics, Bristol Myers Squibb, Grifols, Janssen Pharmaceuticals, Pfizer, Prometheus, Samsung, Takeda Pharmaceutical Co.

Benjamin Click, MD, MS
Benjamin Click, MD, MS
Staff Gastroenterologist
Department of Gastroenterology, Hepatology, and Nutrition
Cleveland Clinic Foundation
Cleveland, OH

Disclosures: Consultant: MedEd, Target RWE; Speakers Bureau: Takeda Pharmaceutical Co.

Madhusudan Grover, MD
Madhusudan Grover, MD
Associate Professor of Medicine & Physiology
Enteric Neuroscience Program
Consultant, Division of Gastroenterology
Mayo Clinic
Rochester, MN

Disclosures: Grant Research Support: Takeda Pharmaceutical Co.

Christina Ha, MD, FACG, AGAF
Christina Ha, MD, FACG, AGAF
Associate Professor of Medicine
The F. Widjaja Foundation Inflammatory Bowel Immunology Research Institute at Cedars-Sinai
Los Angeles, CA

Disclosures: Grant Research Support: Eli Lilly and Co, Pfizer; Consultant: AbbVie, Bristol Myers Squibb, Genentech, InDex Pharmaceuticals, Janssen Pharmaceuticals, Pfizer, Takeda Pharmaceutical Co.

Stephen B. Hanauer, MD
Stephen B. Hanauer, MD
Professor of Medicine
Northwestern University
Chicago, IL

Disclosures: Consultant: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly and Co, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Nestlé Health Science, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Takeda Pharmaceutical Co, TiGenix, UCB, VHsquared; Speakers Bureau: AbbVie, American Regent, Bristol Myers Squibb, Janssen Pharmaceuticals, Pfizer, Takeda Pharmaceutical Co.

Laurie Keefer, PhD
Laurie Keefer, PhD
Professor of Medicine and Psychiatry
GI Health Psychologist
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant Research Support: AbbVie, National Institutes of Health, Patient-Centered Outcomes Research Institute; Consultant: AbbVie, Pfizer; Shareholder: Trellus Health.

Laurent Peyrin-Biroulet, MD, PhD
Laurent Peyrin-Biroulet, MD, PhD
Professor of Medicine
Centre Hospitalier Regional Universitaire Nancy (CHRU Nancy)
Vandoeuvre-lès-Nancy, France

Disclosures: Grant Research Support: AbbVie, Merck Sharp & Dohme, Takeda Pharmaceutical Co; Consultant: AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly and Co, Enterome, Enthera, Ferring Pharmaceuticals, Fresenius Medical Care, Genentech, Gilead Sciences, Hikma Pharmaceuticals, InDex Pharmaceuticals, Janssen Pharmaceuticals, Merck Sharp & Dohme, Mylan, Nestlé Health Science, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna Biologicals, Sublimity Therapeutics, Takeda Pharmaceutical Co, Tillotts Pharma, Vifor Pharma; Shareholder: CTMA.

Sandra Quezada, MD, MS, AGAF
Sandra Quezada, MD, MS, AGAF
Associate Dean for Admissions
Assistant Dean for Faculty Diversity and Inclusion
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
University of Maryland School of Medicine
College Park, MD

Disclosures: Sandra Quezada has no relevant financial relationships with ineligible companies.

Gregory S. Sayuk, MD, MPH
Gregory S. Sayuk, MD, MPH
Associate Professor of Medicine and Psychiatry
Division of Gastroenterology
John T. Milliken Department of Medicine
Washington University School of Medicine
St Louis, MO

Disclosures: Consultant: AbbVie, Alnylam Pharmaceuticals, Ironwood Pharmaceuticals, Salix Pharmaceuticals; Speakers Bureau: AbbVie, Alnylam Pharmaceuticals, Ironwood Pharmaceuticals, Salix Pharmaceuticals.

Nicholas J. Talley, AC, MD (NSW), PhD (Syd), MMedSci (Clin Epi)(Newc.), FAHMS, FRACP, FAFPHM, FRCP (Lond), FRCP (Edin), FACP, MACG, AGAF, FAMS, FRCPI (Hon)
Nicholas J. Talley, AC, MD (NSW), PhD (Syd), MMedSci (Clin Epi)(Newc.), FAHMS, FRACP, FAFPHM, FRCP (Lond), FRCP (Edin), FACP, MACG, AGAF, FAMS, FRCPI (Hon)
Distinguished Laureate Professor
Faculty of Health and Medicine
University of Newcastle, Australia
NHMRC Leadership Fellow, and Chief Investigator NHMRC Centre for Research Excellence in Digestive Health
Senior Staff Specialist
John Hunter Hospital
Newcastle, Australia
Editor in Chief, Medical Journal of Australia
Adjunct Professor of Medicine and Professor of Epidemiology
Mayo Clinic
Rochester, MN
Adjunct Professor
University of North Carolina
Chapel Hill, NC
Foreign Guest Professor
Karolinska Institutet
Stockholm, Sweden

Disclosures: Grant Research Support: National Health and Medical Research Council (NHMRC) to the Centre for Research Excellence in Digestive Health; Consultant: Allakos, Anatara Lifesciences, Arena Pharmaceuticals, Arlyx, Avrio Health, Bayer, BluMaiden Biosciences, Censa Pharmaceuticals, Cadila Pharmaceuticals, Danone, Dr Falk Pharma, Glutagen, HVN National Science Challenge, ISOThrive, Planet Innovation, Progenity, Sanofi-Aventis, Takeda Pharmaceutical Co, twoXAR/Aria Pharmaceuticals, Viscera Labs; Other: Dr Talley has a patent, Biomarkers of IBS licensed (#12735358.9 -1405/2710383 and #12735358.9 -1405/2710384); a patent, Talley Bowel Disease Questionnaire, licensed to Mayo/Talley; a Nestec European Patent license, and a patent Singapore Provisional Patent NTU Ref: TD/129/17 “Microbiota Modulation of BDNF Tissue Repair Pathway” issued and copyright Nepean Dyspepsia Index (NDI) 1998; Editorial: Medical Journal of Australia (editor in chief), UpToDate (section editor), Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea, Med (Journal of Cell Press). Committee participation: Australian Medical Council (AMC) Council Member (2016–2019), MBS Review Taskforce (2016–2020), NHMRC Principal Committee, Research Committee (2016–2021), Asia Pacific Association of Medical Journal Editors (APAME) (current), GESA Board Member (2017–2019). Miscellaneous: Avant Foundation (judging of research grants) (2019). Community and patient advocacy groups: Advisory Board, IFFGD (International Foundation for Functional GI Disorders).

Ryan Ungaro, MD, MS
Ryan Ungaro, MD, MS
Assistant Professor
The Susan and Leonard Feinstein IBD Center
Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Grant Research Support: AbbVie, Boehringer Ingelheim, Pfizer; Consultant: AbbVie, Bristol Myers Squibb, Eli Lilly and Co, Pfizer, Janssen Pharmaceuticals, Takeda Pharmaceutical Co.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By